Hoth Therapeutics Announces Appointment of John Cirrito, PhD, and Carla Yuede, PhD, to Oversee Alzheimer’s Disease Therapeutics Program on Hoth’s Scientific Advisory Board


Dr. Cirrito and Dr. Yuede will oversee the development of HT-ALZ for the treatment of Alzheimer’s disease

NEW YORK, January 31, 2022 /PRNewswire/ — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-centric company biopharmaceutical company, today announced the addition of John Cirritodoctorate and Carla YudePhD to the Scientific Council of the Society.

(PRNewsfoto/Hoth Therapeutics Inc.)

While on the board, Dr. Cirrito and Dr. Yuede will oversee the development of HT-ALZ, an oral therapy in development under the 505(b)(2) regulatory pathway for the treatment of Alzheimer’s disease (AD) and symptoms associated with AD.

Mr. Robb Knie, CEO of Hoth Therapeutics, said, “Hoth is extremely pleased to welcome Dr. Cirrito and Dr. Yuede to our Scientific Advisory Board. Dr. Cirrito and Dr. Yuede are leading researchers in the field of Alzheimer’s disease and we are honored to have their expertise to guide the development of HT-ALZ.”

Dr. Yuede commented: “Finding effective treatments for Alzheimer’s disease is becoming increasingly important and I am delighted to help guide the development of this new therapeutic pathway.

“High beta amyloid is the primary trigger for Alzheimer’s disease. It’s great to be working on a compound that has a direct impact on the cause of this disease,” said Dr. Cirrito.

John Cirrito received his doctorate. in neuroscience at University of Washington in 2005. He has been at the university for 22 years, including his graduate and postdoctoral studies through his current position as full professor of neurology. During his graduate studies, he developed an in vivo microdialysis technique that, for the first time, measured proteins linked to Alzheimer’s disease in a living animal in real time over several days. He did pioneering work to understand how amyloid-beta peptide is regulated in the brain; both production and clearance of the peptide from the brain. In addition to his research lab, John is also director of the Hope Center In Vivo Microdialysis Core Facility at University of Washington who uses microdialysis to help other groups, both academic and corporate, evaluate their compounds on AD-related proteins in mice.

Carla Yude received his doctorate. in behavioral neuroscience University of Missouri – St. Louis in 2006 and completed postdoctoral work on preclinical models of Alzheimer’s disease at the University of Washington. She joined the faculty at University of Washington School of Medicine in 2012 to develop an electrochemical method to study the rapid kinetics of beta-amyloid and other peptides implicated in Alzheimer’s disease pathology. She is co-director of the Animal Behavior Core at the university where she focuses on the assessment of cognitive and behavioral functions in models of neurodegenerative disorders.

Hoth currently has a sponsored research agreement with Dr. Cirrito and Dr. Yuede through University of Washington to perform preclinical proof-of-concept studies for HT-ALZ.

About Hoth Therapeutics, Inc.

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation therapies for unmet medical needs. Hoth’s pipeline development aims to improve the quality of life of patients suffering from indications such as atopic dermatitis, skin toxicities associated with cancer treatment, chronic wounds, psoriasis, asthma, acne, mast cell-derived cancers, anaphylaxis and pneumonia. Hoth has also entered into two different agreements to pursue the development of two therapeutic perspectives to prevent or treat COVID-19. To learn more, please visit

Forward-looking statement

This press release contains forward-looking statements based on Hoth’s current expectations that may constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements relate to Hoth’s business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval for existing product candidates and any other product candidates Hoth may develop, and labeling under any approvals Hoth may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of Hoth’s products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on Hoth’s business, clinical trials, research programs, healthcare systems or the global economy as a whole; Hoth’s intellectual property; Hoth’s reliance on third-party organizations; Hoth’s competitive position; Hoth’s industrial environment; expected financial and operating results of Hoth, including anticipated sources of revenue; Hoth’s assumptions regarding available market size, benefits of Hoth’s products, product pricing, timing of product launches; management’s expectations regarding future acquisitions; statements regarding Hoth’s goals, intentions, plans and expectations, including the introduction of new products and markets; and Hoth’s cash requirements and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by these forward-looking statements. You should not place undue reliance on these forward-looking statements, which include words such as “may”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, ” may”, “continue”, “predict”, “potential”, “project” or similar terms, variations of these terms or the negative of these terms. Although Hoth believes that the expectations reflected in the forward-looking statements are reasonable, Hoth cannot guarantee such results. Hoth may not realize his expectations and his beliefs may not turn out to be correct. Actual results may differ materially from those indicated by these forward-looking statements due to a variety of important factors, including, without limitation, market conditions and the factors described in the section entitled “Risk Factors” in the most recent annual report. of Hoth on Form 10. -Other documents filed by K and Hoth with the United States Securities and Exchange Commission. All such statements speak only as of the date of this press release. Accordingly, forward-looking statements should be viewed only as Hoth’s current plans, estimates and beliefs. Hoth cannot guarantee future results, events, levels of activity, performance or achievement. Hoth does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrence of unforeseen events, except as required by applicable law. .

Investor contacts:
LR Advisors LLC
E-mail: [email protected]
Phone: (678) 570-6791



View original content to download multimedia: -oversee-alzheimers-therapeutic-program-as-part-of-hoth-scientific-advisory-board-301471099.html

SOURCEHoth Therapeutics, Inc.


Comments are closed.